Focuses on developing novel small molecule drugs for oncology and autoimmune diseases, utilizing a proprietary platform to identify and optimize drug candidates.
Eterna Therapeutics Inc. specializes in advancing messenger RNA (mRNA) cell engineering technologies aimed at rectifying cellular dysfunction and addressing various therapeutic indications.
The company's innovative offerings include Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. These technologies pave the way for developing cutting-edge therapies and medicines utillizing gene-editing and cell therapy approaches, with a particular focus on oncology, blood disorders, and monogenic diseases.
Formerly known under a different name, Eterna Therapeutics Inc. rebranded in October 2022. Headquartered in Cambridge, Massachusetts, the company is strategically positioned within the biotechnology hub, driving forward novel mRNA-based solutions to tackle complex medical challenges and improve patient outcomes.